A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

Summary

This is a prospective, parallel-comparison, multi-center, double-masked, randomized, vehicle-controlled dose-response study assessing the safety and ocular hypotensive efficacy of VVN539 in subjects with POAG or OHT. Three different dosing regimens (once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days, each.

Timeline

Start

2022-07-12

Primary completion

2022-12-22

Completion

2022-12-22

Drugs

Indications